2-Cyano-3,12-dioxooleana-1,9-diene-28-oic acid (CDDO) and its derivatives, methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me) and 2-cyano-3,12-dioxooleana-1,9-diene-28-imidazolide (CDDO-Im), are synthetic triterpenoids with antitumorigenic properties in vitro and in vivo.
1,2 CDDO has been reported to decrease the activity of Her2 kinase, disrupt microtubules, induce loss of the inner mitochondrial potential and induce both caspase-dependent and caspase-independent cell death. All three compounds have increased reactive oxygen species (ROS) in various cancer cell lines. CDDO-Me suppressed nuclear factor kB (NF-kB) activity and the mitogenactivated protein kinase pathway, ERK1/2, while activating c-Jun NH 2 -terminal kinase and p38 mitogen-activated protein kinases. This latter activation pattern has been observed in association with ceramide-related stress and cell death in various systems. This study concerns the cytotoxicity of CDDO, CDDOMe and CDDO-Im in an expanded panel of pediatric acute lymphoblastic leukemia (ALL) cell lines. We report that these triterpenoids increased desaturated ceramides in ALL cells predominantly via de novo synthesis, but in a manner not clearly associated with cytotoxicity. Finally, we report that combining CDDO-Im with the cytotoxic retinoid, fenretinide (4-HPR), enhanced 4-HPR-stimulated increase of saturated ceramides (dihydroceramides) and synergized cytotoxicity. These observations suggest that combining CDDO-related triterpenoids with fenretinide resulted in a novel biochemical cellular response worth further preclinical evaluation for the treatment of pediatric ALL.
The cytotoxicity of CDDO (1-10 mM), CDDO-Me (0.1-1.0 mM) and CDDO-Im (0.1-1.0 mM) was tested in the following human pediatric ALL cells and cell lines: MOLT-4 (T-cell, p53 mutated); CCRF-CEM (T-cell); Children's Oncology Group (COG) ALL cell lines, COG-LL-317 (T-cell); COG-LL-319 (pre-B); COG-LL-329 (T-cell), tested as primary cells obtained by peripheral apheresis; and COG-LL-336X (T-cell) and COG-LL-330X (pre-B, second relapse) obtained from primary patient leukemia cells expanded in NOD/SCID mice and harvested for ex vivo cytotoxicity testing. The HL-60 adult acute promyelocytic leukemia cell line was also tested for comparison of results to other reports. Cytotoxicity was determined by a fluorescence-based assay with a 5-log dynamic range in 20% oxygen for CCRF-CEM, MOLT-4 and HL-60 cells, and in 5% oxygen in other cell lines to approximate the oxygen tension of bone marrow. As shown in Figure 1 , the average CDDO concentration that killed 99% of cells (LC 99 ) for CDDO was 4.9 mM (range: 3.8-7.5 mM), for CDDO-Me was 41.0 mM (range: 0.8-41.0 mM) and for CDDOIm was 0.4 mM (range: 0.2-0.6 mM). For acute myeloid leukemia cell line, HL-60, the LC 99 for CDDO was 7.5 mM, for CDDO-Me was 41.0 mM and for CDDO-Im was 0.45 mM. Exposure to CDDO (10 mM) for 4 days caused an average of 3.3 log of cell kill in the seven ALL cells and cell lines; CDDO-Me (1.0 mM) caused an average of 1.7 log of cell kill; CDDO-Im (1.0 mM) caused a median of 4 log of cell kill. Visual microscopic inspection of the assay plates ruled out cytostatic effects. Thus, CDDO and CDDO-Im caused multi-log cell kill in concentration ranges that were most likely achievable clinically, while CDDO-Me had less activity in the concentration range tested.
Because CDDO, CDDO-Me and CDDO-Im have been reported to activate caspases variably in cancer cell lines, caspase activation was examined in the MOLT-4 cells exposed for 2, 6 and 8 h to approximately equally cytotoxic (BLC 99 ) concentrations of drug (CDDO, 5 mM; CDDO-Me, 1 mM; CDDO-Im, 0.4 mM). Caspase-3 activation was observed with CDDO-Me 4CDDO-Im at þ 6 h. Activation of caspase-3, -8 and -9 was observed with all three drugs at þ 8 h, with activation in CDDO-Me and CDDO-Im 4CDDO.
Reactive oxygen species has been reported as contributory to cell death induced by CDDO and derivatives in a variety of solid tumor cell lines. To investigate this, MOLT-4 cells were exposed to BLC 99 concentrations of triterpenoids for 0.5, 2, 4, 6 and 16 h. Cells were then exposed to carboxy-DCFDA (50 mM) and ROS assayed fluorescently by flow cytometry. Hydrogen peroxide (100 mM) treatment for 15 min served as a positive control. Unexpectedly, no increase in ROS was observed.
Because the triterpenoids failed to increase ROS, we investigated whether they increased ceramides in MOLT-4 cells exposed to BLC 99 concentrations of drug for up to 16 h in 20% oxygen. Sphingolipids were labeled with radioactive metabolic precursors, 14 C-palmitic acid or 14 C-serine. Results demonstrated that all three triterpenoids increased (Po0.05) labeled ceramides compared to controls as follows: mean ceramide increase induced by CDDO was B2.4-fold; by CDDO-Me was B2.1-fold; and by CDDO-Im was B8-fold. A time series performed using CDDO-Im (0.4 mM) demonstrated that the increase (Po0.01) of ceramides was progressive with time as follows: þ 2 h, 1.4-fold; þ 4 h, 2.1-fold; and þ 6 h, B3.8 fold compared to controls. Similar results were obtained when assayed in 2% oxygen. As the ceramides increased by the triterpenoids migrated identically on thin-layer chromatography plates to nonradiolabeled desaturated ceramide standards and to the radiolabeled ceramide bands of control cells, they were most likely desaturated (that is, C4,5-trans-double bond) ceramides.
To determine if the ceramides increased via de novo synthesis or from sphingomyelin breakdown, MOLT-4 cells were pretreated for 3 h with myriocin (0.25 mM), an inhibitor of serine palmitoyltransferase, the rate-limiting enzyme of de novo ceramide synthesis, prior to treatment with BLC 99 concentrations of triterpenoids for 16 h. Myriocin almost completely abrogated the increase of labeled ceramides compared to controls, demonstrating that most of the ceramides derived from de novo synthesis. However, to address this further, the sphingomyelins of MOLT-4 cells were pre-labeled with 14 C-serine, and the cells were pretreated with myriocin prior to exposure to CDDO-Im (0.4 mM). Results demonstrated that despite myriocin pretreatment, there was an B1.6-fold increase (Po0.05) of labeled ceramides at þ 16 h, accompanied by a decrease (Po0.01) of labeled sphingomyelins of B25%. These results suggest that a minor portion of the ceramides increased by CDDO-Im derived from sphingomyelin, either as a primary action of CDDO-Im or as a secondary result of cytotoxicity.
Because exogenous treatment with short-chain desaturated ceramides (for example C2 ceramides) or other cellular increase n Combination index, CI o1.
Letters to the Editor do not possess death signaling properties, (2) these ceramides are increased in a cellular compartment that precludes them from effectively acting as death signaling molecules or (3) myriocin was sufficiently disruptive to cellular homeostasis in the context of concurrent triterpenoid exposure that results were confounded. We previously reported that the cytotoxic retinoid, N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR), increased ceramides through stimulation of de novo synthesis and was cytotoxic to cell lines of neuroblastoma and pediatric ALL leukemias while remaining nontoxic to normal fibroblasts and peripheral blood mononuclear cells. 3, 4 In a neuroblastoma cell line, 4-HPR coordinately increased the activity of serine palmitoyltransferase and (dihydro)ceramide synthases (longevity assurance gene homolog family, LASS). 5 Recent investigations have refined the identity of 4-HPR-increased ceramides as saturated (that is dihydro-) ceramides, the immediate precursors of desaturated ceramides, and clarified that 4-HPR simultaneously inhibits dihydroceramide desaturases (DES1 and DES2). [6] [7] [8] Thus, 4-HPR treatment results in an increase of cellular ceramides, accompanied by a shift from unsaturated ceramides to dihydroceramides. However, the relationship between 4-HPR-induced dihydroceramides and cytotoxicity is not clear, as long-chain dihydroceramides are not cell penetrant, precluding the direct testing of their cytotoxicity. Further, the death signaling properties of a ceramide species may depend on the exact cellular compartment of its generation (exogenous, de novo, acidic vs neutral sphingomyelinase, mitochondrial and so on).
Since both CDDO-Im and 4-HPR stimulated de novo ceramide synthesis and as 4-HPR inhibits the conversion of dihydroceramides into ceramides, we hypothesized that combining the two agents would cause a greater increase in dihydroceramides than with 4-HPR alone. Further, if long-chain dihydroceramides act as a cytotoxic principle for 4-HPR, we reasoned that 4-HPR þ CDDO-Im would have greater cytotoxicity compared to the sum of either agent alone. The effects on ceramide increase and cytotoxicity of 4-HPR þ CDDO-Im in MOLT-4 cells are shown in Figure 2 . Mass spectroscopy analysis of MOLT-4 cells treated with 4-HPR alone revealed a striking increase of dihydroceramides (dhC14-dhC26) in a chain lengthspecific manner with a concurrent decrease of most ceramides (Figure 2a) . By thin-layer chromatography assay, this was visualized as the loss of the lower (slowest migrating) of the two labeled ceramide bands observed in controls, and by the appearance of a third, faster migrating, band containing exclusively very long chain dihydroceramides (Figure 2b ). Single agent 4-HPR (5 mM) induced a B10-fold increase in labeled ceramides in MOLT-4 cells at þ 16 h, predominantly as dihydroceramides (Po0.01). CDDO-Im (0.4 mM) increased ceramides B4-fold (Po0.01), primarily as ceramides. Interestingly, when 4-HPR (5 mM) was combined with CDDO-Im (0.4 mM), the slowest migrating (lower) of the two ceramide bands observed in control cells was lost (as observed with 4-HPR alone), and there was a larger increase in total ceramides than with either single agent alone (B25-fold at þ 16 h compared to controls, Po0.01), due to an increase in the intensity of the upper, fastest migrating, dihydroceramide band and the middle (mixed ceramides) band. These results suggest that both drugs act in at least an additive manner to increase de novo ceramide synthesis while 4-HPR simultaneously inhibits dihydroceramide desaturase activity, leading to a greater increase in dihydroceramides. In dose-response assays, a fixed concentration of 4-HPR (5 mM) synergized the cytotoxicity of CDDO-IM (0-1 mM) in MOLT-4 cells (Figure 2c ). While the data are only correlative, the concurrent increase in dihydroceramides observed with 4-HPR þ CDDO-Im, coupled with the synergistic increase of cytotoxicity, suggests that native long-chain dihydroceramides may contribute to cytotoxicity. It cannot be excluded, however, that other pro-death properties of CDDO-Im acted to synergize 4-HPR cytotoxicity independently of effects on the quantity and/or species distribution of cellular ceramides.
Irregardless, the cytotoxicities of these three triterpinoids to pediatric ALL cells and cell lines, together with the synergistic cytotoxicities exhibited by CDDO-Im þ 4-HPR in MOLT-4 cells, suggest that expanded preclinical testing of these agents in pediatric ALL cells is warranted. Future clinical studies of these agents in combination with fenretinide will be facilitated by the new intravenous and oral formulations of fenretinide currently in Phase I trials supported by the NCI RAID program.
DNA breakage at chromosomal fragile sites (CFS) is believed to promote oncogenic chromosome rearrangement. Notable CFS involvement in leukemia-lymphoma (LL) includes deletions affecting WWOX (located within FRA16D), which is also fused with IGH via t(14;16)(q32;q23) in multiple myeloma, and FHIT at 3p14 (FRA3D) in B-cell lymphoma. Both lesions operate as tumor suppressors and, unlike key LL rearrangements, occur widely in solid tumors. Only 19/89 CFS have been cloned and their coordinates pinpointed. 1 Recent mapping data now show that FRA8C, another leading candidate CFS in LL, lies outside the MYC breakpoint cluster at 8q24. 2 Hence, there remain tantalizingly few leukemic oncogene chromosome rearrangements definitively mapped within CFS. We describe t(3;7) (q27;q32) in a B-cell lymphoma cell line, which fuses BCL6 to a conserved non-coding region within FRA7H, to serve as a unique model for neoplastic fragile site involvement in LL.
The RC-K8 cell line was established from a 55-year-old man with terminal diffuse large B-cell lymphoma (DLBCL) diagnosed originally as 'true histiocytic lymphoma' (www.dsmz.de). Gbanding and chromosome painting revealed the following karyotype: 47, XY, der(Y)t(Y;5)(qter;?p15), der(?1)t(1;13)(p32;q11) del(1)(q11), del(2)(p11p13), dup(2)(p11-12p14-15), t(3;7) (q27;q32), der(5)inv(5)(q15q32)add(5)(q32), inv(5)(p?13q?32), der(8)(t(8;8)(p12;q11), del(9)(p24)x2, der(10)t(9;10)(?p24;p11), À13, t(11;14)(q23;q32), der(14)t(X;14)(p11;p11), À15, der(15) (t(X;15)(p11.3;p11), add(17)(p11), der(20)t(13;20)(q11;q13), þ 2mar. The t(3;7), shown in Figure 1a , is clearly visible in the early passage originators' karyotype where it was then interpreted as t(3;4) indicating stability.
Fluorescence in situ hybridization (FISH) using bacterial artificial chromosome (BAC) and fosmid clones showed that the break at 3q27 lay within BAC RP11-211G11 and fosmid WI2802L21, which both cover the BCL6 major breakpoint Clastogenesis favored normal chromosomes, occurring in 17/500 cells (3.4%) compared to 4/500 cells (0.8%) in der(3)/der(7), implying stabilization therein by the formation of t(3;7).
